Background: Australis is one of the most prevalent strains infecting dogs, leading, in natural conditions, to severe life-threatening cases.
Objective: The objective was to evaluate the onset and duration of immunity (OOI and DOI) induced by a new licensed quadrivalent antileptospiral vaccine (EURICAN L4) including four components (Canicola, Icterohaemorrhagiae, Grippotyphosa and Australis) against Australis. To this end, a severe Australis challenge model was developed, using a canine strain recently isolated from the field.
In 2020, a new 0.5 mL presentation of PUREVAX® RCP FeLV was registered and introduced in Europe. The objectives of this study were to investigate the local safety of this non-adjuvanted vaccine at reduced volume by classical methods (clinical examination, histopathology) and to evaluate the suitability of an alternative non-invasive methodology, the computed tomography (CT).
View Article and Find Full Text PDFObjective: To analyse the risk of incident vertebral and non-vertebral fracture in men with DISH.
Methods: In 782 men ages 50-85 years, DISH was diagnosed using Resnick's criteria. In men followed prospectively for 7.